SCHEMBL20220596

SCHEMBL20220596

CC(C)OC(=O)N1CCC(N2CCc3cc(F)ccc3C2)CC1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 3/20 0.51
GPR119 Q8TDV5 5/20 0.48
DPP9 Q86TI2 3/20 0.41
DPP4 P27487 2/20 0.41
DPP8 Q6V1X1 2/20 0.41
DPP7 Q9UHL4 1/20 0.41
ACACB O00763 1/20 0.41
ACACA Q13085 1/20 0.41
ABHD6 Q9BV23 2/20 0.40
CHRM2 P08172 2/20 0.40
OPRM1 P35372 1/20 0.40
OPRK1 P41145 1/20 0.40
OPRL1 P41146 1/20 0.40
CHRM1 P11229 1/20 0.40
HRH3 Q9Y5N1 1/20 0.39
NAMPT P43490 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20220626 0.86 ABHD6 (0.54) ADRA1AGPR119ABHD6CHRM2CHRM1
SCHEMBL20220386 0.85 ADRA1A (0.48) ADRA1AGPR119ACACBACACAABHD6
SCHEMBL3768604 0.84 ESR2 (0.53) ADRA1AGPR119HRH3NAMPT
SCHEMBL2573737 0.82 ADRA1A (0.52) ADRA1ADPP9DPP4DPP8HRH3
SCHEMBL20220387 0.81 CHRM2 (0.52) ADRA1AGPR119ABHD6CHRM2CHRM1
SCHEMBL16824264 0.80 NR1H2 (0.52) ADRA1AGPR119HRH3
SCHEMBL18186148 0.77 ADRA1A (0.52) ADRA1ADPP9DPP4DPP8HRH3
SCHEMBL20312212 0.73 ADRA1A (0.47) ADRA1ADPP9DPP4DPP8DPP7
SCHEMBL16835561 0.73 ADRA1A (0.68) ADRA1AHRH3NAMPT
SCHEMBL28099009 0.73 CXCR3 (0.45) ADRA1AHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3083592-B1 SUBSTITUTED PIPERIDINYL-TETRAHYDROQUINOLINES AND THEIR USE AS ALPHA-2C ADRENORECEPTOR ANTAGONISTS Bayer Pharma AG (DE) 2018-06-27 EP disclosed
EP-3329920-A2 ADRENORECEPTOR ALPHA2C RECEPTOR ANTAGONISTS Bayer Pharma Aktiengesellschaft (DE) 2018-06-06 EP disclosed